Meeting
2020 ASCO Virtual Scientific Program
Randomized, phase II study of ficlatuzumab with or without cetuximab in patients with pan-refractory, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Authors
Julie E. Bauman
University of Arizona Cancer Center, Tucson, AZ
Julie E. Bauman , Denise Roe , Nabil F. Saba , Jessica Ruth Bauman , John M. Kaczmar , Barbara Burtness , Jameel Muzaffar , Ricklie Ann Julian , Steven Wang , Shethal Bearelly , Audrey Baker , Conor Ernst Steuer , Aarti K. Bhatia , Anshu Giri , Carlos Caulin , Laura P. Stabile , Sara Centuori , Christine H. Chung
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03422536
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS6594)
DOI
10.1200/JCO.2020.38.15_suppl.TPS6594
Abstract #
TPS6594
Poster Bd #
255
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase I study of the anti-HGF monoclonal antibody (mAb), ficlatuzumab, and cetuximab in cetuximab-resistant, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
First Author: Julie E. Bauman
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy and safety of CetuGEX in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC): Results from the randomized phase II RESGEX study.
First Author: Ulrich Keilholz
Poster
2016 ASCO Annual Meeting
An international, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 2 study of palbociclib (an oral CDK4/6 inhibitor) plus cetuximab in patients with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).
First Author: Bhumsuk Keam
Poster
2016 ASCO Annual Meeting
Phase II trial of carboplatin/paclitaxel and cetuximab, followed by carboplatin/paclitaxel/cetuximab and erlotinib, in metastatic or recurrent squamous cell carcinoma of the head and neck.
First Author: Aarti K. Bhatia